New Bayer, Regeneron Eye Drug Gets EU Agency Backing

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Friday, September 21, 2012

Reuters

EU drugs regulators have recommended Regeneron's and Bayer's eye drug Eylea for approval in a move likely to see the new medicine eat away further at rival Roche's market share.

Full Story

Which of the following is not a potential complication after cataract surgery with implantation of a multifocal IOL:
1. Irvine-Gas syndrome
2. Z-syndrome
3. Halos
4. Decreased contrast sensitivity
Check The Answer

Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product
OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

New Bayer, Regeneron Eye Drug Gets EU Agency Backing

Comments

Quick Quiz

Which of the following is not a potential complication after cataract surgery with implantation of a multifocal IOL:

AdGlare RMR Ad

Featured Products

Smartphone-Based Retinal Screening System

OPMI LUMERA 700 Surgical Microscope

Follow OphthalmologyWeb

Write for Us

AdGlare RMR2